FlandersBio on Twitter

Follow us on Twitter

Archive for April 2013 - News

Archive for April 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

NYSE Liffe lists Equity Options on Galapagos

30.04.2013

Today NYSE Liffe, the Europe-based derivatives business of NYSE Euronext (NYX), added options on the shares of Galapagos (Euronext: GLPG), a clinical stage biotech company focused on developing novel medicines, to its highly successful range of equity option classes. The options are available on the Brussels derivatives market of NYSE Liffe under the ticker GLS. read more

Galapagos completes private placement by issuance of 2,696,831 new ordinary shares

30.04.2013

Galapagos NV (Euronext: GLPG) announces that it has completed its capital increase by issuing today 2,696,831 new ordinary shares. These shares will be delivered to Belgian and international institutional and other eligible investors who participated in the €53.9 million private placement closed on Wednesday 24 April 2013. The newly issued shares were admitted to listing on NYSE Euronext Brussels and NYSE Euronext Amsterdam on 29 April 2013. read more

CRYO-SAVE FACILITATES THE FIRST TRANSPLANTATION IN SPAIN TO TREAT BLACKFAN-DIAMOND ANAEMIA THANKS TO THE COST-FREE DONATION PROGRAM

29.04.2013

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international stem cell storage company and the largest family stem cell bank in Europe, announced a stem cell transplantation in Spain to treat Blackfan-Diamond Aneamia. It is the first time in Spain that this congenital anaemia, classified as a rare disease, has been treated using cord blood stem cells which were stored with Cryo-Save. read more

JO DALLE BENOEMD TO GENERAL MANAGER VAN GENZYME’S PRODUCTIESITE IN GEEL

29.04.2013

Met ingang van 1 mei 2013 wordt Jo Dalle benoemd tot Vice President en General Manager van Genzyme in Geel. read more

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013

26.04.2013

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that Professor Hans de Haard (Chief Scientific Officer) and Dr. Debbie Allen (Senior Director, Business Development) will each present at the Ninth Annual PEGS (Protein Engineering Summit). The event takes place April 29-May 3, 2013 at the Seaport World Trade Center (Boston, MA, USA). read more

Galapagos raises €54 million

25.04.2013

Galapagos NV (Euronext: GLPG) announced today that it has raised €53.9 million through a private placement of new shares via an accelerated bookbuilding procedure announced on 24 April 2013. read more

Galapagos to raise capital via a private placement of new shares

25.04.2013

Galapagos NV (Euronext: GLPG) today announced the launch of a private placement of new shares to institutional investors for a targeted amount of €40 million. The Company may extend this amount but will in no event place in excess of 10% of the current number of outstanding shares (i.e. no more than 2,696,831 new shares will be issued). Jefferies International Limited and Kempen & Co. will be acting as Joint Global Coordinators and Joint Bookrunners for the offering. read more

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

25.04.2013

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print